GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ABUS · Jun 30, 2025

Arbutus Biopharma Corp. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001447028-25-000115General Corporate

Debt relative to revenue100thOwn-history percentile · N=10

Evidence method

Level · gp.fundamentals.debt_to_revenue

0.00% · OPTIONAL · VALID

Capex intensity20thOwn-history percentile · N=10

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.00% · OPTIONAL · VALID

Operating cash generation90thOwn-history percentile · N=10

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-146.65% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

522.19% · CORE · NOT_ENOUGH_HISTORY

Operating margin100thOwn-history percentile · N=10

Evidence method

Level · gp.fundamentals.operating_margin

13.86% · CORE · VALID

R&D intensity0thOwn-history percentile · N=10

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

51.20% · OPTIONAL · VALID

SBC intensity0thOwn-history percentile · N=10

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

7.11% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History11 statesHistory building

Dec 31, 20230/7 normalizedLevel 3 Mar 31, 20240/7 normalizedLevel 3 Jun 30, 20240/7 normalizedLevel 3 Sep 30, 20240/7 normalizedLevel 3 Dec 31, 20246/7 normalizedLevel 3 Mar 31, 20256/7 normalizedLevel 3 Jun 30, 20256/7 normalizedLevel 3 Sep 30, 20256/7 normalizedLevel 3 Dec 31, 20257/7 normalizedLevel 3 Mar 31, 20266/6 normalizedLevel 3 Jun 30, 20266/6 normalizedLevel 3

Period transition

What moved in the state?

Cash Generation Increased

Previous: -759.13%
Current: -146.65%
Delta: 612.47%

Growth Increased

Previous: 15.14%
Current: 522.19%
Delta: 507.05%

Profitability Increased

Previous: -1456.86%
Current: 13.86%
Delta: 1470.72%

R And D Intensity Decreased

Previous: 507.88%
Current: 51.20%
Delta: -456.68%

Sbc Intensity Decreased

Previous: 202.04%
Current: 7.11%
Delta: -194.93%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · ABUS Fundamental State →Transitioned To · ABUS Fundamental State →Transitioned To · ABUS CASH_GENERATION_INCREASED →Transitioned To · ABUS GROWTH_INCREASED →Transitioned To · ABUS PROFITABILITY_INCREASED →Transitioned To · ABUS R_AND_D_INTENSITY_DECREASED →Transitioned To · ABUS SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.